- **1** Neopterin and Biochemical parameters as indicators of predicting HIV disease
- 2 progression and treatment response: A cross-sectional study in Ghana

3 ABSTRACT

- Background: Surrogate markers have been identified as having significance in the pathogenesis and prognosis of HIV infection. But there is limited data on the utility of neopterin estimation in HIV infection. Therefore the study sought to measure and ascertains the trend of serum neopterin and other biochemical parameters as indicators of predicting HIV disease progression and treatment response
- 8 among HIV seropositive individuals.
- 9 Methods: A cross-sectional study in 298 HIV seropositive individuals consisting of 165 HIV on highly 10 active antiretroviral treatment and 136 naïve highly active antiretroviral patients. Venous blood was taken 11 for the assay neopterin and the other biochemical parameters.
- **Results:** Neopterin was significantly lower (p=0.0001) in patients placed on the highly active antiretroviral therapy than the naïve highly active antiretroviral therapy patients. Serum neopterin was found to increase as the disease progresses and decreases as duration of the therapy treatment increases (p=0.0001). At cut of point of 54.5nmol/L, neopterin gave a sensitivity of 97.5%, specificity of 95.9% and an area under the curve of 0.99.
- 17 Conclusion: Neopterin has shown to be to be good marker in predicting the HIV disease progression 18 especially in patients with CD4 counts less than 200mm⁻³ and useful indicator of patient's response to 19 therapy treatment.
- 20 **Keywords:** Neopterin, Human Immunodeficiency Virus (HIV), Highly Active Antiretroviral therapy 21 (HAART), CD4 counts
- 22

23 INTRODUCTION

- HIV infection has been a challenge to the medical fraternity in the last three decades [1]. The use of
- 25 HAART in the treatment of HIV infected individuals has also resulted in a number of adverse effects [2, 3],
- 26 hence the clinical assessment of the impact of HAART has become necessary in the management of
- 27 people living with HIV infection.
- 28 Several studies have shown the value of prognostic markers such as CD4 counts, viral RNA loads and 29 soluble markers of immune activation in predicting the disease progression [4, 5] but the principal 30 biomarker marker used in the monitoring of HIV infected individuals is the CD4 count. However, CD4 31 counts estimation is relatively expensive and require considerable skills as compared to other soluble 32 biomarkers hence few laboratories in resource limited settings offer the test for patients making the 33 clinical monitoring of patients difficult [6-8]. Considering the fact that HIV infection is mostly endemic in 34 poor developing/third world countries where resources and infrastructures are limited, there is the need 35 for cost effective, easily performed and readily available surrogate markers that can assist in predicting 36 the disease progression and patient's response to HAART.
- A major feature of HIV infection is the activation of all component of the immune system and an increasedproduction of several surrogate cytokines which are indications of immunologic changes in the body
- 39 during the HIV infection. However, due to the limitation in the ability to measure circulating cytokines has

40 led to the determination of products of immune activation which reflect cytokine activity [9]. Such 41 assessment includes soluble biomarkers and one such candidate marker is neopterin. Neopterin is a 42 metabolite of guanosine triphosphate produced by macrophages and dendritic cells upon activation of 43 gamma interferon. Hence it considered as a marker of immune activation and correlate with the disease 44 progression [7, 10].

As neopterin levels reflect the degree of immune deficiency in HIV-positive patients, and perhaps the response to ART, the question was asked whether neopterin has indeed, as claimed elsewhere [11, 12], prognostic value concerning the HIV disease progression. It was against this premise that we evaluated serum neopterin and other biochemical parameters among HIV seropositive on HAART and HAART naïve HIV patients in other to ascertain the trends of these markers in HIV disease progression.

50

51 MATERIALS AND METHODS

52 STUDY DESIGN

This was a cross sectional study carried out at the ART clinic of the Bomso Specialist hospital in the Ashanti region of Ghana from August 2015 to March 2016. Bomso Specialist hospital is staffed by registered general nurses, medical doctors, medical assistance, laboratory technicians, nutritionist, surgeons, health assistants, psychiatrist, optometrist and laborers. The department presently used by the hospital for it service provision are the outpatients department (OPD), in-patient department, maternity wing, laboratory unit, pharmacy department, a theater, a psychiatry unit, an x-ray unit and a mortuary 59

60 STUDY POPULATION

Non-probability sampling technique was used to recruit a total of 298 confirmed HIV seropositive individuals consisting of 162 HIV HAART patients and 136 HIV HAART naïve patients. Patients who were confirmed HIV seropositive and were 18 and above were recruited into the study. Patients with coinfection such hepatitis B, C, tuberculosis and pregnant women were excluded from the study. All participants were placed into three groups according to the center for disease control classification which indicates the CD4 lymphocytes of patients. The groups were; CD4 counts less than 200mm⁻³, CD4 count between 200 and 499mm⁻³ and the third group consisted of patients with CD4 above 500mm⁻³.

68 DATA COLLECTION AND LABORATORY ANALYSIS

A well-structured questionnaire was used to obtain demographic and clinical characteristics from the patients. 5ml of venous blood were taken from each patient under sterile conditions after a tourniquet has been applied for less than a minute. 2 ml out of the blood taken was place in an anti-coagulated sequestrene bottles-EDTA for CD4 and CD3 analysis using the Becton Dickenson and company haematological analyzer called the BD FACS Count from California in USA. The remaining blood was centrifuged after they have been made to clot in a plain test tube. The serum obtained was stored at - 20°C for the assay of neopterin (ELISA) and the other biochemical parameters using an auto-analyzer
 known as ATAC® 8000 Random Chemistry System from USA by Elan Diagnostic System.

77 DATA ANALYSIS

The data were presented as median interquartile range (IQR) for non-parametric variables whiles grouped variables were expressed as proportions. Comparison between HAART naïve and HAART patients was carried out using Mann Whitney U test. Spearman correlation rank test was used to assess correlations between variables. A suitable cut off point were determined for neopterin using the Youden's index. The performance of neopterin was assessed using the area under the curve from the receiver operator characteristics. P-value less than 0.05 was statistically considered to be significant. All the analysis was performed using the statistical package for social sciences version 20.

85 **RESULTS**

86 The socio-demographic and clinical characteristics of the studied population are shown in table 1. Out of 87 the two hundred and ninety eight (298) participants, there were more females than male for both the 88 HAART (70.2%) and the HAART naïve patients (69.3%). There was no statistically significance difference 89 between the age of the HAART and HAART naïve group (p=0.203). The median CD4 counts of the HAART group (458 mm⁻³) was significantly (p=0.0001) higher than the HAART naïve group (229 mm⁻³). 90 91 Although the median BMI was not statically significant (p=0.521), the HAART group had a higher BMI (23.30 kg/m²) compared to the HAART naïve group (22.55kg/m²). None of the studied participants had a 92 93 history of smoking and drinking. There was also no incidence of therapy discontinuation among the 94 HAART group [Table 1].

Table 2 shows comparison of biochemical parameters of the HAART group and HAART naïve group. Serum neopterin of the HAART naïve patients (51.70nmol/L) was significant higher (p=0.0001) than the HAART patients (26.40nmol/L). Serum albumin was significantly higher in the HAART group than the HAART naïve group (p=0.0001) whiles all the other biochemical parameters were significantly lower (p=0.0001) in the HAART patients compared to the HAART naïve patients.

Among the HAART group, patients on Tenofovir, Lamivudine and Nevirapine combination had the lowest mean serum levels 27.7nmol/L whiles patients on Zidovudine, Lamivudine and Nevirapine combination had the highest mea serum neopterin levels of 45.nmol/L **[Figure 1].**

Table 3 shows the comparison of the biochemical parameters with the respective CD4 counts in the HAART and HAART naïve patients. Neopterin was found to be increased as the disease progresses as measured by the respective CD4 counts in both the HAART and the HAART naïve patients. Elevated neopterin values were found in patients whose CD4 counts were below 200mm⁻³ whiles lowest values were found in patients with CD4 counts \geq 500mm⁻³ in both the HAART (17.20nmol/L) and the HAART naïve patients (21.40nmol/L).All the biochemical parameters except albumin were also increased as thedisease progresses.

Table 4 shows correlation of neopterin with CD4, biochemical parameters and some clinical factors. A significant negative correlation was observed between neopterin and CD4 count for both HAART (r= -0.99, p=0.0001) and HAART naïve patients (r= -0.96, p=0.0001). Correlation of serum neopterin with albumin, BMI and the duration of therapy treatment also showed significant negative correlation for both the HAART and the HAART naïve subjects. All the other biochemical parameters correlated positively to neopterin significantly except urea which did not show any significant correlation with serum neopterin in the HAART naïve patients.

Figure 2 shows the duration on HAART and serum neopterin levels among the HAART patients. Neopterilevels decreases as the duration of HAART increases.

Table 5 shows the predictive performance of serum neopterin in predicting CD4 counts <200mm⁻³. The diagnostic accuracy of serum neopterin in predicting CD4 less than 200mm⁻³ was found to be 83.9% . At cut off point of 55.4nmol/L, the sensitivity and specificity were found to be 97.5% and 95.9% respectively for the total participants. The area under the curve were also 0.99,1.0 and 0.98 for the total subject, HAART and HAART naïve patients repectively. From figure 2, neopterin levels were also found to be decreased as the duration of the therapy increases with patients being on the therapy for more than four having the lowest serum neopterin levels (24.20nmol/L) followed by those who have been on the therapy between two and four years (28.90nmol/L). Highest neopterin values were found in patients who have been on the therapy for less than two years (32.80nmol/L).On the contrary CD4 count was increased as the duration on the therapy increases.

Parameter	HAART group(162)	HAART naïve(136)	P value	
Age(years)	41 (35-53)	40 (31.3-50)	0.203	
Gender				
Male	48(29.8%)	42(30.7%)		
Female	114(70.2%)	94(69.3%)		
$CD4 (mm^{-3})$	458.00(307.50-633.75)	229.00(136.25-338.75)	0.0001	
CD3 (mm ⁻³)	1216.50(931.00-1765.50)	919.00(667.50-1143.00)	0.0001	
$BMI kg/m^2$)	23.30(20.33-26.85)	22.55(19.13-26.98)	0.521	
HAART regime				
TDF+3TC+NVP	94(57.7)			
AZT+3TC+ NVP	9(5.8)			
CBV+NVP	28(17.3)			
TDF+3TC+EFV	31(19.2)			
HAART duration(yrs.)				
Median(IQR)	5(3-7)			
Group1(<2)	10(5.2)			
Group2 (2-4)	35(18.2)			
Group 3(>4)	59(30.7)			
Duration of diagnosis(yrs.)				
Median(IQR)	5(3-8)	1(0.45-2)		
Group1(<2)	6(3.1)	53(27.6)		
Group2 (2-4)	33(17.2)	31(16.1)		
Group 3(>4)	65(33.9)	4(2.1)		
Smoking				
Alcohol				
Drug discontinuation				

144 Table 1: Socio-demographic and Clinical characteristics of the studied participants

145 CD4- cluster of differentiation, IQR-interquartile range, CBV: Combivir, NVP: Nevirapine, EFV:

146 Efavirenz, 3TC: Lamivudine, TDF: Tenofovir, AZV: Zidovudine.

147	Table 2: Com	parison of biochemical	parameters of the HAART	group and HAART naïve group)
-----	--------------	------------------------	-------------------------	-----------------------------	---

Parameter	HAART group	HAART naïve	P value
Neopterin (nmol/L)	26.40(18.95-39.83)	51.75(35.60-67.70)	0.0001
Albumin (g/L)	40.05(36.50-41.28)	34.75 (32.10-39.10)	0.0001
Globulin (g/L)	57.00(48.95-74.98)	84.35 (69.83-92.03)	0.0001
Total Protein (g/L)	97.40(89.13-110.60)	118.90 (100.33-127.30)	0.0001
AST (U/L)	14.00(13.00-18.75)	23.00 (15.00-35.75)	0.0001
ALT (U/L)	10.00(8.00-14.00)	15.50 (10.00-25.00)	0.0001
Urea (mmol/L)	2.70(2.30-3.20)	3.20 (2.70-4.60)	0.0001
Creatinine (µmol/L)	62.00(55.00-69.75)	71.50 (62.00-84.50)	0.0001

148 AST-Aspartate amino Transferase, ALT-Alanine amino Transferase.

CD4 Count								
	< 200	200-499	\geq 500					
Parameters HAART naïve								
Neopterin(nmol/L)	70.10(63.43-79.63)***	43.00(30.40-49.40) †††	21.40(19.55-23.55)###					
Albumin(g/L)	32.10(30.33-33.20)***	36.40(34.30-39.30)††	40.20(39.70-40.35)###					
Globulin(g/L)	88.05(83.63-97.03)***	81.40(60.10-90.10)††	55.10(49.90-58.50)###					
Total protein(g/L)	119.70(116.60-127.40)	119.90(98.30-127.20)†	95.20(89.75-98.75)###					
AST(UI/L)	25.50(20.50-44.00)**	18.00(14.00-30.00)†	13.00(11.00-14.5)##					
ALT(UI/L)	21.00(12.25-28.50)**	13.00(10.00-23.00)†	8.00(7.50-10.00)##					
Urea(mmol/l)	3.60(2.65-5.10)	3.20(2.90-4.40)††	2.60(2.30-2.65)#					
Creatinine(umol/l)	76.00(65.50-99.75)	68.00(62.00-82.00)††	55.00(53.50-60.00)##					
		HAART group						
Neopterin(nmol/L)	70.10(60.13-75.50)***	32.60(27.45-41.15)†††	17.20(12.75-20.55)###					
Albumin(g/L)	31.30(30.27-33.18)***	38.70(35.80-40.05)†††	41.20(40.25-42.45)###					
Globulin(g/L)	86.05(75.73-89.90) **	64.80(57.75-80.55)†††	48.20(42.55-52.85)###					
Total protein(g/L)	117.20(102.43-121.53)	97.40(100.70-119.90)†††	89.10(84.35-94.15)###					
AST(UI/L)	19.50(16.00-29.75)	17.00(14.00-20.00)†††	13.00(11.50-14.00)###					
ALT(UI/L)	17.50(10.25-26.50)	12.00(10.00-14.00)†††	9.00(8.00-9.00)##					
Urea(mmol/l)	2.95(2.28-5.13)	3.10(2.90-3.60)†††	2.3.00(2.20-2.50)#					
Creatinine(umol/l)	69.00(57.00-85.25)	68.00(66.00-79.00)†††	55.00(53.00-57.50)###					

Table 3: Comparison of the biochemical parameters with the respective CD4 counts in theHAART and HAART naïve patients.

151 $**P \le 0.01$, $***P \le 0.0001$ indicate level of significance when CD4 count < 200 was compared with CD4

152 200-499, $\dagger P \le 0.05$, $\dagger \dagger P \le 0.01$, $\dagger \dagger \dagger P \le 0.0001$ indicate level of significance when CD4 count 200-499

153 was compared with CD4 count \geq 500, $\#P \leq 0.05$, $\#\#P \leq 0.01$, $\#\#P \leq 0.0001$ indicate level of significance

154 when CD4 count < 200 was compared with CD4 \geq 500.

155

156 **Table 4** Correlation of Neopterin with CD4, biochemical parameters and some clinical factors.

Neopterin	HAAR	T group	HAAR	T naïve	CD4 with	HAAR	T group	HAAR	T naïve
with	r	P value	r	P value	-	r	P value	R	P value
CD4	-0.995	0.0001	-0.964	0.0001					
Albumin	-0.786	0.0001	-0.674	0.0001	Albumin	0.797	0.0001	0.696	0.0001
Globulin	0.866	0.0001	0.426	0.0001	Globulin	-0.868	0.0001	-0.552	0.0001
Protein	0.802	0.0001	0.580	0.0001	Protein	-0.803	0.0001	-0.390	0.0001
AST	0.577	0.0001	0.507	0.0001	AST	-0.592	0.0001	-0.508	0.0001
ALT	0.506	0.0001	0.475	0.0001	ALT	-0.521	0.0001	-0.478	0.0001
Urea	0.741	0.0001	0.124	0.250	Urea	-0.749	0.0001	-0.132	0.219
Creatinine	0.766	0.0001	0.263	0.013	Creatinine	-0.764	0.0001	-0.254	0.017
BMI	-0.225	0.022	-0.516	0.0001	BMI	0.218	0.026	0.462	0.0001
DT	-0.289	0.003			DT	0.297	0.002		

157 r: correlation coefficient, BMI-Body mass index, DT –duration of HAART treatment

158

159

160

UNDER PEER REVIEW

1		1	1	U		
	Cut off	Sen	Spec	PPV	NPV	AUC
Total subjects	55.4nmol/L	97.5%	95.9%	0.913	0.815	0.99
HAART group	58.0nmol/L	100%	100%	0.90	0.904	1.00
HAART naïve	59.5nmol/L	91.7%	100%	0.806	0.942	0.98


Table 5: Predictive performance of serum neopterin in predicting CD4 counts <200mm⁻³

Sen; sensitivity, Spec; specificity, Accu; Accuracy, PPV; Positive predictive value, NPV; Negative

164


163

predictive value, AUC; Area under the curve




165

166 **Figure 1** HAART types and their mean serum neopterin levels



168



170 DISCUSSION

171 Serum albumin levels in the HAART patients was appreciably higher than the HAART naïve patients 172 (p=0.0001). Albumin levels were found to be decreased as the disease progresses. These findings tie 173 with earlier reports by [13, 14]. Low albumin levels may be explained by poor nutritional status. Other 174 possible mechanisms for decreased albumin may be due to the persistent inflammatory response caused 175 by the infection. Also since the concentrations of acute phase protein are decreased in chronic 176 inflammation as a result of elevation in cytokines level which imposes the liver to channel other proteins 177 needed for immune response, it was not surprise that albumin levels were decreased as the infection 178 progresses given the fact that albumin is a negative acute phase protein. The serum globulin levels of the 179 HAART naïve patients were significantly higher than the HAART experienced patients. Consistent with 180 this study, other previous cross sectional studies that have evaluated serum globulins have found 181 reduction in serum globulin in HAART patients compared to HAART naïve patients [15, 16]. Serum 182 globulins were found to be increased as the disease progresses. This observation could be attributed to 183 the chronic immune activation and B cell dysfunction which induces hypergamaglobulinemia via 184 polyclonal B cell activation leading to a spontaneous increase in immunoglobulins which may result in the 185 elevation of serum globulin in the HAART naïve patients [17] Both AST and ALT of the HAART naïve 186 patients was higher than the HAART patients. This concur with earlier findings by Osakunor et al. [18] 187 and inconsistent with [2, 19].

There was no statistical difference in the body mass index of the HAART and HAART naïve patients (p=0.502). BMI was found to correlate positively with CD4 count for both the HAART and HAART naïve patients. Concurrent with this finding, previous study have reported higher BMI to be associated with increased CD4 counts as well as improved immune reconstitution and survival resulting in a slower

UNDER PEER REVIEW

disease progression [20-22]. The strong positive correlation between BMI and CD4 count is indicative that increased BMI may be associated with immunological improvement and a reduction in both immune activations contributing to a decrease in serum neopterin levels. In support of this, the study found serum neopterin to correlate negatively with CD4 count for both the HAART and the HAART naïve patients.

196 Serum neopterin levels was significantly lower in patients who were on the highly active antiretroviral 197 therapy than the naïve highly active antiretroviral patients (p=0.0001). This result correlates well with 198 studies by [23] and N Amirayan-Chevillard, et al. [24] who showed that HAART significantly decrease 199 circulating levels of neopterin by 30 % (61.7nmol/L and 88.1nmol/L for HAART and HAART naïve 200 respectively). HIV infection is associated with a continuous immune activation which stimulates the 201 release of inflammatory cytokines thereby increasing the total level of neopterin in the HAART naïve 202 group. Several explanations could be attributed to the increased immune activation seen in HIV infection. 203 At the site of HIV infection, there is migration of tissue peripheral CD4 cells which results in the activation 204 of macrophages. This leads to a reduction in the peripheral blood CD4 cells thereby contributing to a 205 persistent immune activation. Neopterin levels were found to be increased as the disease progresses with higher median values in patients with CD4 counts <200 mm⁻³ and this collaborate with studies by Chadha 206 207 et al [7] who also reported higher neopterin values in patients with CD4 counts less than 200mm⁻³. This 208 elevation could be due to the stimulatory role of y IFN in the synthesis of neopterin [25] and the link 209 between chronic elevation of y IFN and HIV disease progression [12]. Mildvan et al [10] also reported that 210 elevated baseline neopterin levels are linked with increased risk of HIV disease progression and indicate 211 the predictive value of neopterin in the disease progression.

Among the HAART patients, the study observed a significant positive correlation between CD4 and the 212 213 duration on the therapy (rho 0.297, p=0.002) whiles a negative significant correlation was observed 214 between the duration on the therapy and neopterin (rho -0.289, p=0.003). This is thus indicative that 215 increased duration on HAART may result in an increase in CD4 and a decline in serum neopterin levels. 216 This is consistent with earlier report by [11] Several mechanisms have been proposed as to the effect of 217 these therapies on the serum neopterin levels of patients infected with HIV. In a randomized doubled 218 blind study aimed at evaluating the effect of HAART treatment on the human immunodeficiency virus, 219 Collier et al. [26] found HAART to be associated with an increase in the CD4 T lymphocyte cells and a 220 decline in markers of immune activation which promotes a partial recovery in functions of the immune 221 cells. This was consistent with the results which found CD4 count to be increased among HAART patients 222 than the HAART naive subject and a decrease in neopterin levels among the HAART patients. In another 223 cross sectional study, the functions of the lymphoid progenitor cells including the differentiation into the B 224 and T lymphocytes have also been shown to normalize among HIV patients treated with the highly active 225 antiretroviral therapy [27]. HAART has been shown to induce changes in the T helper 1 and T helper 2 226 which differentiate to produce cytotoxic T cells and antibodies respectively [28] and also reverses the 227 defects in the CD4 cells [29]. The cumulative effect of these mechanisms of HAART on the immune cells is the restoration of interleukin 2 productions which modulate various aspect of the immune response [30] and a decline in the level of cytokines involved in the pathogenesis of HIV infection. Consequently there is

- a reduction in the immune activation and the circulating levels of serum neopterin in HIV infected
- individuals [12]. Although HAART was associated with a decrease in serum neopterin levels, the usage of
- 232 Tenofovir, Lamivudine and Nevirapine combination resulted in a much more decrease in serum neopterin
- 233 levels compared with the other HAART combinations used in this study.

234 CONCLUSION

235 Neopterin levels were elevated in HAART naïve patients compared to HAART patients. Increased 236 neopterin levels were associated with a decline in CD4 count and correlated with severity of the disease 237 progression whiles longer duration on the therapy was associated with an increase in CD4 count and a decline in neopterin levels. Neopterin has shown to be a useful biomarkers in predicting the HIV disease 238 progression especially in patients with CD4 counts less than 200mm⁻³ and a useful indicator of patient's 239 240 response to therapy treatment. Regular measurement of serum neopterin and other biochemical 241 parameters could provide some prognostic information on the disease progression enhancing close 242 monitoring and therapeutic interventions for individuals with a greater possibility of progressing with the 243 disease in resource limited settings.

244 CONSENT FOR PUBLICATION

245 Not Applicable

246 ETHICAL APPROVAL

Ethical approval was sought from the management of Bomso specialist Hospital and the committee on human research and publication of the School of medical science, Kwame Nkrumah University of Science and Technology (KNUST). Participation was voluntary and verbal informed consent was obtained from each participant according to Helsinki declaration. Respondents were assured that the information gathered was to be used strictly for research and academic purpose only. In addition, respondents were given the freedom to opt out any time they thought they couldn't continue with the study.

253 **REFERENCE**

- 255 1. UNAIDS: HIV Epidemic Update. Geneva. 2002.
- Ngala RA, Opoku D, Asare G: Effects of HIV Infection and Highly Active Antiretroviral Therapy (HAART) on the Liver of HIV Patients. *Trends in Medical Research* 2015, 10(1):1-11.
- 258 3. Ejilemele A, Nwauche C, Ejele O: Pattern of abnormal liver enzymes in HIV patients presenting at 259 a Nigerian Tertiary Hospital. *The Nigerian postgraduate medical journal* 2007, 14(4):306-309.
- Fuchs D, Albert J, Åsjö B, Fenyö E, Reibnegger G, Wachter H: Association between serum neopterin concentrations and in vitro replicative capacity of HIV-1 isolates. *Journal of Infectious Diseases* 1989, 160(4):724-725.

- 5. Fahey JL: Cytokines, plasma immune activation markers, and clinically relevant surrogate
 markers in human immunodeficiency virus infection. *Clinical and diagnostic laboratory immunology* 1998, 5(5):597-603.
- Balakrishnan P, Solomon S, Kumarasamy N, Mayer KH: Low-cost monitoring of HIV infected individuals on highly active antiretroviral therapy (HAART) in developing countries. *Indian Journal* of Medical Research 2005, 121(4):345.
- Chadha S, Bhalla P, Gautam H, Chakravarti A, Saini S, Anuradha S, Dewan R: Utility of Serum
 Neopterin and Serum IL-2 Receptor Levels to Predict Absolute CD4 T Lymphocyte Count in HIV
 Infected Cases. *Interdiscip Perspect Infect Dis* 2013, 2013:143648.
- 8. Malone JL, Simms TE, Gray GC, Wagner KF, Burge JR, Burke DS: Sources of variability in repeated T-helper lymphocyte counts from human immunodeficiency virus type 1-infected patients: total lymphocyte count fluctuations and diurnal cycle are important. *JAIDS Journal of Acquired Immune Deficiency Syndromes* 1990, 3(2):144-151.
- 276 9. Chandra I, Lalitha V, Chelvi KS, Padmapriyadarsini C: Serum neopterin levels in HIV infected
 277 patients with & without tuberculosis. *Indian Journal of Medical Research* 2005, 121(4):220.
- Mildvan D, Spritzler J, Grossberg SE, Fahey JL, Johnston DM, Schock BR, Kagan J: Serum neopterin, an immune activation marker, independently predicts disease progression in advanced HIV-1 infection. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 2005, 40(6):853-858.
- Bipath P, Viljoen M, Levay PF: Levels of procalcitonin, C-reactive protein and neopterin in patients with advanced HIV-1 infection. *Southern African Journal of HIV Medicine* 2012, 13(2):78-82.
- 285 12. Wirleitner B, Schroecksnadel K, Winkler C, Fuchs D: Neopterin in HIV-1 infection. *Mol Immunol* 2005, 42(2):183-194.
- 13. Mehta SH, Astemborski J, Sterling TR, Thomas DL, Vlahov D: Serum albumin as a prognostic indicator for HIV disease progression. *AIDS Research & Human Retroviruses* 2006, 22(1):14-21.
- 289 14. Olawumi HO, Olatunji PO: The value of serum albumin in pretreatment assessment and 290 monitoring of therapy in HIV/AIDS patients. *HIV Med* 2006, 7(6):351-355.
- 15. Jacobson MA, Khayam-Bashi H, Martin JN, Black D, Ng V: Effect of long-term highly active
 antiretroviral therapy in restoring HIV-induced abnormal B-lymphocyte function. *Journal of acquired immune deficiency syndromes* 2002, 31(5):472-477.
- Serpa J, Haque D, Valayam J, Breaux K, Rodriguez-Barradas MC: Effect of combination antiretroviral treatment on total protein and calculated globulin levels among HIV-infected patients. *International Journal of Infectious Diseases* 2010, 14:e41-e44.
- 297 17. Moir S, Fauci AS: B cells in HIV infection and disease. *Nature reviews Immunology* 2009, 9(4):235-245.
- Osakunor DNM, Obirikorang C, Fianu V, Asare I, Dakorah M: Hepatic Enzyme Alterations in HIV
 Patients on Antiretroviral Therapy: A Case-Control Study in a Hospital Setting in Ghana. *PloS one* 2015, 10(8):e0134449.
- Lucien K, Clement A, Fon N, Weledji P, Ndikvu C: The effects of antiretroviral treatment on liver
 function enzymes among HIV-infected out patients attending the Central Hospital of Yaounde,
 Cameroon. African Journal of Clinical and Experimental Microbiology 2010, 11(3).
- Jones CY, Hogan JW, Snyder B, Klein RS, Rompalo A, Schuman P, Carpenter CC, Group
 HIVERS: Overweight and human immunodeficiency virus (HIV) progression in women:
 associations HIV disease progression and changes in body mass index in women in the HIV
 epidemiology research study cohort. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 2003, 37 Suppl 2(Supplement 2):S69-80.
- Koethe JR, Jenkins CA, Shepherd BE, Stinnette SE, Sterling TR: An optimal body mass index
 range associated with improved immune reconstitution among HIV-infected adults initiating
 antiretroviral therapy. *Clinical infectious diseases* 2011:cir606.
- Denue B, Ikunaiye P, Denue C: Body mass index changes during highly active antiretroviral therapy in Nigeria/Modifications de l'indice de masse corporelle pendant le traitement antirétroviral hautement actif au Nigéria. *Eastern Mediterranean Health Journal* 2013, 19(3):S89.
- Bipath P, Levay P, Olorunju S, Viljoen M: A non-specific biomarker of disease activity in
 HIV/AIDS patients from resource-limited environments. *African health sciences* 2015, 15(2):334-343.

- 319 24. Amirayan-Chevillard N, Tissot-Dupont H, Obadia Y, Gallais H, Mege JL, Capo C: Highly active 320 antiretroviral therapy (HAART) and circulating markers of immune activation: specific effect of 321 HAART on neopterin. Clin Diagn Lab Immunol 2000, 7(5):832-834.
- 322 25. Murr C WB, Wirleitner B, Fuchs D.: Neopterin as a marker for immune system
- 323 activation. Curr Drug Metab 2002, 3:175-187.
- 324 Collier AC, Coombs RW, Schoenfeld DA, Bassett RL, Timpone J, Baruch A, Jones M, Facev K, 26. 325 Whitacre C, McAuliffe VJ et al: Treatment of human immunodeficiency virus infection with 326 saguinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. The New England journal of 327 *medicine* 1996, 334(16):1011-1017.
- 328 27. Nielsen SD, Ersbøll AK, Mathiesen L, Nielsen JO, Hansen J-ES: Highly active antiretroviral 329 therapy normalizes the function of progenitor cells in human immunodeficiency virus-infected 330 patients. Journal of Infectious Diseases 1998, 178(5):1299-1305.
- 331 28. Pakker NG, Notermans DW, de Boer RJ, Roos MT, de Wolf F, Hill A, Leonard JM, Danner SA, 332 Miedema F, Schellekens PT: Biphasic kinetics of peripheral blood T cells after triple combination 333 therapy in HIV-1 infection: a composite of redistribution and proliferation. Nat Med 1998, 4(2):208-334 214.
- 335 Autran B. Carcelain G. Li TS. Blanc C. Mathez D. Tubiana R. Katlama C. Debre P. Leibowitch J: 29. 336 Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997, 277(5322):112-116. 337
- Daniel V, Süsal C, Melk A, Weimer R, Kröpelin M, Zimmermann R, Huth-Kühne A, Uhle C, Opelz 338 30. 339 G: Reduction of viral load and immune complex load on CD4+ lymphocytes as a consequence of highly active antiretroviral treatment (HAART) in HIV-infected hemophilia patients. Immunology 340 341 letters 1999, 69(2):283-289.
- 342
- 343
- 344
- 345
- 346
- 347